Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).

Wang M., Jurczak W., Jerkeman M., Trotman J., Zinzani P. L., Walewski J. A., ...Daha Fazla

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 Haziran 2022 identifier

  • Yayın Türü: Bildiri / Özet Bildiri
  • Basıldığı Ülke: ELECTR NETWORK
  • Ankara Üniversitesi Adresli: Evet